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Inorganic nitrate supplementation 
lowers blood pressure
Kapil et al., Hypertension 2010; 56: 274–281; doi:10.1161/
HYPERTENSIONAHA.110.153536
Despite the understanding that elevated blood pressure is a 
major risk factor for cardiovascular disease and for the pro-
gression of chronic kidney disease (CKD), blood pressure 
remains elevated in about half of all treated hypertensive 
patients. The situation is even worse in patients with CKD, so 
any therapy that could lower blood pressure in these patients 
would be most welcome. A variety of studies have strongly 
suggested that consumption of vegetable-rich diets confers 
protection from cardiovascular disease, including hyper-
tension. The exact mechanisms of the blood pressure-lowering 
and protective effects of such diets remain uncertain. It was 
recently suggested that dietary nitrate found in high levels in 
vegetables might underlie some of these effects. With this in 
mind, Kapil et al. performed a randomized crossover study in 
which the effects of nitrate supplementation by KNO3 (ver-
sus KCl) or vegetable intake (250 ml of beetroot juice with 
5.5 mmol nitrate versus 250 ml of water) on plasma nitrite 
concentration, cyclic guanosine monophosphate (cGMP) 
concentration, and blood pressure were examined in healthy 
volunteers. They found that ingestion of KNO3 capsules or 
vegetable intake increased circulating plasma nitrate (Figure, 
top) and nitrite concentrations and that it substantially low-
ered blood pressure (Figure, bottom), an effect that lasted 
more than 24 hours. These changes were not seen when a 
similar dose of KCl was administered, which suggests that the 
KNO3-induced blood pressure changes were not attributable 
to the K+ content and were, more likely, due to the endogenous 
conversion to nitrite and, thus, to NO. They also found a tem-
poral relationship between the increases in circulating nitrite 
concentration and a rise in cGMP levels. As cGMP is a most 
sensitive indicator of NO bioactivity, its elevation provided 
unequivocal evidence of the generation of bioactive NO.
The study thus demonstrates a dose-dependent decrease 
in blood pressure and vasoprotection after inorganic nitrate 
ingestion, either in the form of supplementation or by dietary 
elevation.
Juan Oliver
Intensive blood pressure control in 
hypertensive chronic kidney disease
Appel et al., N Engl J Med 2010; 363: 918–929
Elevated blood pressure and the progression of CKD have a 
strong association. The African American Study of Kidney 
Disease and Hypertension (AASK) evaluated the effects of 
two blood pressure targets and three different primary anti-
hypertensive medications on the progression of CKD among 
black patients with hypertensive kidney disease. All patients 
enrolled were black and had hypertensive CKD. Potential sub-
jects with diabetes mellitus were excluded. During the trial 
phase, subjects were randomized to a target blood pressure of 
130/80 mm Hg or 140/90 mm Hg and separately randomized 
to one of three initial drug therapies: ramipril, metoprolol, or 
amlodipine. At the beginning of the cohort phase, all patients 
were switched to ramipril and had their blood pressure tar-
geted to 140/90 mm Hg or below. The target blood pressure 
was subsequently reduced to less than 130/80 mm Hg in 2004, 
concurrently with publication of national guidelines. The pri-
mary outcome for this combined analysis of trial and cohort 
data was the progression of CKD (defined as a doubling of 
serum creatinine), the development of end-stage renal disease, 
or death. Combining both phases of the study, no significant 
differences between blood pressure control groups were seen 
with respect to the primary outcome (hazard ratio for the 
lower blood pressure group, 0.91; 95% confidence interval 
(CI), 0.77–1.08). Interestingly, the effects of blood pressure 
target interacted with baseline protein-to-creatinine ratio, 
indicating that the effect of blood pressure target was differ-
ent on the basis of the level of initial urinary protein excre-
tion. Among participants with minimal proteinuria (urinary 
protein-to-creatinine ratio ≤0.22), no significant difference 
between the two blood pressure target arms was seen (hazard 
ratio, 1.18; 95% CI, 0.93–1.50). However, among participants 
who had elevated levels of urine protein excretion (urine pro-
tein-to-creatinine ratio >0.22), those in the lower blood pres-
sure target group had a significant reduction in the primary 
outcome (hazard ratio, 0.73; 95% CI, 0.58–0.93).
Effects of KNO3 on circulating plasma nitrate (top) and systolic blood 
pressure (SBP; bottom).
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Although subgroup analyses inherently have limitations, the 
biological plausibility of the mechanism of diseases for which 
proteinuria serves as a marker strongly supports the validity of 
the conclusion that more intensive blood pressure control confers a 
benefit with regard to progression. Consistent with current clinical 
practice guidelines, these data support a goal blood pressure of less 
than 130/80 mm Hg in patients with proteinuria.
Lynda Szczech
Interventional therapy for 
hypertension due to fibromuscular 
dysplasia renal artery stenosis
Trinquart et al., Hypertension 2010; 56: 525–532; doi:10.1161/
HYPERTENSIONAHA.110.152918
Renal artery stenosis hypertension due to fibromuscular 
dysplasia (FMD) is a rare condition that likely includes a 
heterogeneous group of idiopathic, non-atherosclerotic 
diseases of the musculature of arterial walls, leading to 
the narrowing of small- and medium-sized arteries. After 
atherosclerosis, FMD is the most frequent cause of renal 
artery stenosis that causes hypertension. Whereas athero-
sclerotic renal artery stenosis frequently affects elderly 
patients with renal parenchymal disease, FMD renal stenosis 
predominantly affects young to middle-aged women with 
normal kidney function. On the basis of the seminal experi-
ments by Goldblatt, removal of the stenosis should lead 
to restoration of normal blood pressure in these patients. 
Indeed, renal artery revascularization has been frequently 
used either to cure hypertension or to improve blood pressure 
control. However, for a variety of reasons, the efficacy and 
potential complications of stenosis correction have not been, 
and are unlikely to be, rigorously tested. Hence, a recent com-
munication analyzing the accumulated clinical experience of 
interventional therapy is welcome. Trinquart et al. performed 
a systematic review of studies in which hypertensive patients 
with FMD renal artery stenosis underwent percutaneous 
transluminal renal angioplasty or surgical reconstruction. 
They assessed the frequency of periprocedural complications 
and whether hypertension improvement or cure occurred. 
They selected 47 angioplasty studies (with 1616 patients) and 
23 surgery studies (with 1014 patients). The combined rates 
of hypertension cure, defined according to the criteria in each 
study, were 46% (95% CI, 40–52%) after angioplasty and 58% 
(95% CI, 53–62%) after surgery, with substantial variations 
across studies. The probability of being ‘cured’ was nega-
tively associated with patient age and time of publication. 
Cure rates using the definition of a blood pressure less than 
140/90 mm Hg without treatment were only 36% and 54% 
after angio plasty and surgery, respectively. The combined 
risks of periprocedural complications were 12% after angio-
plasty and 17% after surgery, with fewer major complications 
after angioplasty than after surgery (6% versus 15%).
This analysis shows that angioplasty or surgical revascular-
ization yielded moderate benefits in patients with hyper-
tension due to FMD renal artery stenosis, with substantial 
variation across studies and with the blood pressure outcome 
being strongly influenced by patient age. Moreover, the inci-
dence of complications was substantial. Given the efficacy of 
current medical antihypertensive therapy, caution in recom-
mending intervention in these patients may be warranted.
Juan Oliver
Aquaporin-3 mediates  
hydrogen peroxide uptake  
to regulate downstream 
intracellular signaling
Miller et al., Proc Natl Acad Sci USA 2010; 107: 15681–15686; doi:10.1073/
pnas.1005776107
Hydrogen peroxide (H2O2) may act not only as a molecule 
involved in oxidative stress and in the organism’s defense and 
immune responses but may also represent a physiological 
effector in essential cellular processes. In these two different 
functions, H2O2 is generated by different systems and acts 
through different effector systems. For example, H2O2 pro-
duced by cell-surface NADPH oxidase enzymes is emerging 
as an important signaling molecule for growth, differentiation, 
and migration processes such as those required for wound 
healing. However, how cells spatially regulate H2O2 to achieve 
physiological redox signaling over nonspecific oxidative stress 
pathways is insufficiently understood. Recently, Miller et al. 
reported that aquaporin-3 (AQP3), a member of the water 
channel family, can facilitate the uptake of H2O2 into mam-
malian cells and mediate downstream intracellular signaling. 
Using molecular imaging techniques, they directly demon-
strated that the aquaporin isoforms AQP3 and AQP8, but 
not AQP1, can promote uptake of H2O2 specifically through 
membranes in mammalian cells. The intracellular H2O2 accu-
mulation can be modulated up or down on the basis of AQP3 
expression, which in turn can influence H2O2 downstream cell 
signaling in response to growth factor stimulation.
Taken together, these findings demonstrate that the down-
stream intracellular effects of H2O2 can be regulated by AQP3 
acting as a carrier across cell-membrane barriers, allowing 
H2O2 to act as an intracellular second messenger in a man-
ner distinct from its function as a reactive oxygen species in 
nonspecific oxidative stress.
Detlef Schlöndorff
